Pregnant women with abnormal vaginal flora Pregnancy and Childbirth Other inflammation of vagina and vulva
Conditions
Interventions
1. Experimental Group: Daily oral intake of one capsule containing Lactobacillus rhamnosus GR-1 (GR-1®) and Lactobacillus reuteri RC-14 (RC-14®). The dosage at end-of-shelf-life is 1 × 109 colony form
Sponsors
University Children's Hospital Tübingen (Germany)
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Pregnant women, resident within the study area at the time of enrolment and being attending a medical practice located within the study area (A random selection process will assure representativeness of recruiting practices and, hence, external validity) 2. Over 18 years 3. Less than 12 completed weeks of pregnancy (WOP) 4. Written informed consent
Exclusion criteria
Exclusion criteria: 1. Active chronic inflammatory bowel disease (M. Crohn, Colitis ulcerosa) 2. Immunodeficiency
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Restoration from asymptomatic pathologic vaginal flora to a normal lactobacilli colonisation and an increase in lactobacilli in the vaginal flora after 8 weeks of intervention. | — |
Countries
Germany
Outcome results
None listed